The targeting of oncogene-addicted cancers such as EGFR-driven lung cancer or ELM4-ALK-driven lung cancer has resulted in major improvements in patient outcomes, yet tumor regression can be short lived in some cases and acquired resistance is nearly always observed (Sequist et al, 2011). The gene discussed is ALK; the disease is cancer.